ليتروزول تيڤع

Země: Izrael

Jazyk: arabština

Zdroj: Ministry of Health

Aktivní složka:

LETROZOLE 2.5 MG

Dostupné s:

TEVA PHARMACEUTICAL INDUST.LTD

ATC kód:

L02BG04

Léková forma:

TABLETS

Podání:

PER OS

Výrobce:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapeutické skupiny:

LETROZOLE

Terapeutické indikace:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Datum autorizace:

2010-01-01